These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

702 related articles for article (PubMed ID: 19015207)

  • 21. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA).
    Mease PJ; Fleischmann R; Deodhar AA; Wollenhaupt J; Khraishi M; Kielar D; Woltering F; Stach C; Hoepken B; Arledge T; van der Heijde D
    Ann Rheum Dis; 2014 Jan; 73(1):48-55. PubMed ID: 23942868
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Certolizumab pegol in the treatment of rheumatoid arthritis: a comprehensive review of its clinical efficacy and safety.
    Mease PJ
    Rheumatology (Oxford); 2011 Feb; 50(2):261-70. PubMed ID: 20871129
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Adalimumab plus methotrexate for the treatment of rheumatoid arthritis: a multi-center randomized, double-blind, placebo-controlled clinical study.].
    Huang F; Zhang FC; Bao CD; Tao Y; Gu JR; Xu JH; Zhu P; Xu HJ; Zhang ZY; Zhao DB; Wu DH
    Zhonghua Nei Ke Za Zhi; 2009 Nov; 48(11):916-21. PubMed ID: 20079321
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study.
    Weinblatt ME; Fleischmann R; Huizinga TW; Emery P; Pope J; Massarotti EM; van Vollenhoven RF; Wollenhaupt J; Bingham CO; Duncan B; Goel N; Davies OR; Dougados M
    Rheumatology (Oxford); 2012 Dec; 51(12):2204-14. PubMed ID: 22923753
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression.
    Atsumi T; Yamamoto K; Takeuchi T; Yamanaka H; Ishiguro N; Tanaka Y; Eguchi K; Watanabe A; Origasa H; Yasuda S; Yamanishi Y; Kita Y; Matsubara T; Iwamoto M; Shoji T; Okada T; van der Heijde D; Miyasaka N; Koike T
    Ann Rheum Dis; 2016 Jan; 75(1):75-83. PubMed ID: 26139005
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5-year results from the RAPID 1 trial and open-label extension.
    Keystone E; Landewé R; van Vollenhoven R; Combe B; Strand V; Mease P; Shaughnessy L; VanLunen B; van der Heijde D
    Ann Rheum Dis; 2014 Dec; 73(12):2094-100. PubMed ID: 23918037
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of certolizumab pegol in combination with methotrexate in methotrexate-inadequate responder Chinese patients with active rheumatoid arthritis: 24-week results from a randomised, double-blind, placebo-controlled phase 3 study.
    Bi L; Li Y; He L; Xu H; Jiang Z; Wang Y; Li X; Wei W; Gu J; Wang G; Zhang Z; Zhou B; Liu Y; Wu Z; Liu H; He D; Lv Z; Li Z; Zuo X; Dong L; Wu H; Zhang H; Chen H; Bao C; Zhang Z; Zhang M; Song H; Zheng Y; Jiang L; Liu X; Boehnlein M; Dunkel J; Shao J; Harris K; Li Z
    Clin Exp Rheumatol; 2019; 37(2):227-234. PubMed ID: 30183595
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rapid onset of efficacy predicts response to therapy with certolizumab plus methotrexate in patients with active rheumatoid arthritis.
    Kang YM; Park YE; Park W; Choe JY; Cho CS; Shim SC; Bae SC; Suh CH; Cha HS; Koh EM; Song YW; Yoo B; Lee SS; Park MC; Lee SH; Arendt C; Koetse W; Lee SK
    Korean J Intern Med; 2018 Nov; 33(6):1224-1233. PubMed ID: 29294598
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Certolizumab pegol: a review of its use in the management of rheumatoid arthritis.
    Deeks ED
    Drugs; 2013 Jan; 73(1):75-97. PubMed ID: 23338540
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Certolizumab pegol plus methotrexate provides broad relief from the burden of rheumatoid arthritis: analysis of patient-reported outcomes from the RAPID 2 trial.
    Strand V; Smolen JS; van Vollenhoven RF; Mease P; Burmester GR; Hiepe F; Khanna D; Nikaï E; Coteur G; Schiff M
    Ann Rheum Dis; 2011 Jun; 70(6):996-1002. PubMed ID: 21415050
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of different imputation approaches on the evaluation of radiographic progression in patients with psoriatic arthritis: results of the RAPID-PsA 24-week phase III double-blind randomised placebo-controlled study of certolizumab pegol.
    van der Heijde D; Fleischmann R; Wollenhaupt J; Deodhar A; Kielar D; Woltering F; Stach C; Hoepken B; Arledge T; Mease PJ
    Ann Rheum Dis; 2014 Jan; 73(1):233-7. PubMed ID: 23942869
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial.
    Keystone EC; Kavanaugh AF; Sharp JT; Tannenbaum H; Hua Y; Teoh LS; Fischkoff SA; Chartash EK
    Arthritis Rheum; 2004 May; 50(5):1400-11. PubMed ID: 15146409
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Maintenance therapy with certolizumab pegol for Crohn's disease.
    Schreiber S; Khaliq-Kareemi M; Lawrance IC; Thomsen OØ; Hanauer SB; McColm J; Bloomfield R; Sandborn WJ;
    N Engl J Med; 2007 Jul; 357(3):239-50. PubMed ID: 17634459
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vaccine responses in patients with rheumatoid arthritis treated with certolizumab pegol: results from a single-blind randomized phase IV trial.
    Kivitz AJ; Schechtman J; Texter M; Fichtner A; de Longueville M; Chartash EK
    J Rheumatol; 2014 Apr; 41(4):648-57. PubMed ID: 24584918
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study.
    Smolen JS; Burmester GR; Combe B; Curtis JR; Hall S; Haraoui B; van Vollenhoven R; Cioffi C; Ecoffet C; Gervitz L; Ionescu L; Peterson L; Fleischmann R
    Lancet; 2016 Dec; 388(10061):2763-2774. PubMed ID: 27863807
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial.
    Ritchlin C; Rahman P; Kavanaugh A; McInnes IB; Puig L; Li S; Wang Y; Shen YK; Doyle MK; Mendelsohn AM; Gottlieb AB;
    Ann Rheum Dis; 2014 Jun; 73(6):990-9. PubMed ID: 24482301
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patients.
    Smolen JS; van Vollenhoven R; Kavanaugh A; Strand V; Vencovsky J; Schiff M; Landewé R; Haraoui B; Arendt C; Mountian I; Carter D; van der Heijde D
    Arthritis Res Ther; 2015 Sep; 17(1):245. PubMed ID: 26353833
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rapid improvement in the signs and symptoms of rheumatoid arthritis following certolizumab pegol treatment predicts better longterm outcomes: post-hoc analysis of a randomized controlled trial.
    Keystone EC; Curtis JR; Fleischmann RM; Furst DE; Khanna D; Smolen JS; Mease PJ; Schiff MH; Coteur G; Davies O; Combe B
    J Rheumatol; 2011 Jun; 38(6):990-6. PubMed ID: 21362764
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Certolizumab pegol: new drug. As a last resort in Crohn's disease: continue to use other TNF alpha inhibitors.
    Prescrire Int; 2009 Jun; 18(101):108-10. PubMed ID: 19637418
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study.
    Landewé R; Braun J; Deodhar A; Dougados M; Maksymowych WP; Mease PJ; Reveille JD; Rudwaleit M; van der Heijde D; Stach C; Hoepken B; Fichtner A; Coteur G; de Longueville M; Sieper J
    Ann Rheum Dis; 2014 Jan; 73(1):39-47. PubMed ID: 24013647
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.